Guardian Pharmacy Services, Inc. (NYSE:GRDN - Get Free Report) shares saw strong trading volume on Monday . 364,615 shares changed hands during trading, an increase of 109% from the previous session's volume of 174,150 shares.The stock last traded at $20.55 and had previously closed at $20.65.
Analyst Upgrades and Downgrades
Several research analysts recently issued reports on the stock. Truist Financial reiterated a "buy" rating and set a $28.00 price target (up previously from $25.00) on shares of Guardian Pharmacy Services in a research report on Monday, May 19th. Wall Street Zen downgraded shares of Guardian Pharmacy Services from a "buy" rating to a "hold" rating in a research report on Saturday, May 24th. Finally, Raymond James set a $28.00 price target on shares of Guardian Pharmacy Services and gave the stock an "outperform" rating in a research report on Wednesday, May 14th.
Get Our Latest Analysis on Guardian Pharmacy Services
Guardian Pharmacy Services Trading Down 1.7%
The business's 50-day simple moving average is $23.20 and its 200-day simple moving average is $22.00.
Guardian Pharmacy Services (NYSE:GRDN - Get Free Report) last released its earnings results on Monday, May 12th. The company reported $0.21 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.22 by ($0.01). The business had revenue of $329.31 million for the quarter, compared to the consensus estimate of $321.21 million. Equities research analysts anticipate that Guardian Pharmacy Services, Inc. will post 0.87 earnings per share for the current year.
Insider Buying and Selling at Guardian Pharmacy Services
In related news, Director William E. Bindley sold 651,454 shares of the stock in a transaction that occurred on Wednesday, May 28th. The shares were sold at an average price of $20.16, for a total value of $13,133,312.64. Following the sale, the director now directly owns 1,939,817 shares in the company, valued at $39,106,710.72. This trade represents a 25.14% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, Director John Ackerman sold 201,303 shares of the stock in a transaction that occurred on Wednesday, May 28th. The shares were sold at an average price of $20.16, for a total transaction of $4,058,268.48. Following the completion of the sale, the director now owns 149,794 shares in the company, valued at $3,019,847.04. This represents a 57.34% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 11,344,912 shares of company stock worth $228,713,426. Company insiders own 63.71% of the company's stock.
Institutional Trading of Guardian Pharmacy Services
Hedge funds have recently modified their holdings of the company. GAMMA Investing LLC acquired a new stake in Guardian Pharmacy Services during the 1st quarter worth approximately $170,000. BNP Paribas Financial Markets acquired a new stake in Guardian Pharmacy Services during the 4th quarter worth approximately $37,000. Compass Financial Services Inc acquired a new stake in Guardian Pharmacy Services during the 4th quarter worth approximately $58,000. JPMorgan Chase & Co. acquired a new stake in Guardian Pharmacy Services during the 4th quarter worth approximately $77,000. Finally, Quantbot Technologies LP acquired a new stake in Guardian Pharmacy Services during the 4th quarter worth approximately $81,000.
About Guardian Pharmacy Services
(
Get Free Report)
Guardian Pharmacy Services, Inc, a pharmacy service company, provides a suite of technology-enabled services designed to help residents of long-term health care facilities (LTCFs) in the United States. Its individualized clinical, drug dispensing, and administration capabilities are used to serve the needs of residents in lower acuity LTCFs, such as assisted living facilities and behavioral health facilities and group homes.
Read More
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Guardian Pharmacy Services, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Guardian Pharmacy Services wasn't on the list.
While Guardian Pharmacy Services currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
